Success Metrics

Completion Rate
0%(0/1)
Active Trials
5(83%)
Terminated
1(17%)

Phase Distribution

Ph phase_3
1
17%
Ph phase_2
3
50%
Ph not_applicable
2
33%

Phase Distribution

0

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
1(16.7%)
N/ANon-phased studies
2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

5

trials recruiting

Total Trials

6

all time

Status Distribution
Active(5)
Terminated(1)

Detailed Status

Recruiting3
Active, not recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
5
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (50.0%)
Phase 31 (16.7%)
N/A2 (33.3%)

Trials by Status

terminated117%
active_not_recruiting233%
recruiting350%

Recent Activity

5 active trials
Showing 5 of 6
active_not_recruitingphase_3

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

NCT03233711
active_not_recruitingphase_2

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

NCT04929028
recruitingphase_2

Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment

NCT07405476
recruitingnot_applicable

MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate Cancer

NCT05438563
recruitingphase_2

FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery

NCT06780787
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03233711Phase 3

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

Active Not Recruiting
NCT04929028Phase 2

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Active Not Recruiting
NCT07405476Phase 2

Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment

Recruiting
NCT05438563Not Applicable

MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate Cancer

Recruiting
NCT06780787Phase 2

FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery

Recruiting
NCT02419846Not Applicable

Informed Decision Making Intervention in Screening for Prostate Cancer of Predominantly African American Participants in a Community Outreach Program

Terminated

All 6 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
6